 | |
| Clinical data | |
|---|---|
| Trade names | Yorvipath |
| Other names | ACP-014, TransCon PTH |
| AHFS/Drugs.com | Yorvipath |
| License data | |
| Routes of administration | Subcutaneous |
| Drug class | Hormonal agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism.[1][2] It is a transiently pegylated parathyroid hormone.[4] It is a parathyroid hormone analog.[1]
Palopegteriparatide was approved for medical use in the European Union in November 2023,[2] and in the United States in August 2024.[1][5]
- ^ a b c d "Yorvipath injection, solution". DailyMed. 14 August 2024. Retrieved 5 September 2024.
- ^ a b c Cite error: The named reference
Yorvipath EPARwas invoked but never defined (see the help page). - ^ "Yorvipath Product information". Union Register of medicinal products. 20 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
- ^ Cite error: The named reference
Yorvipath: Pending EC decisionwas invoked but never defined (see the help page). - ^ "FDA approves new drug for hypoparathyroidism, a rare disorder". U.S. Food and Drug Administration (FDA) (Press release). 9 August 2024. Archived from the original on 13 August 2024. Retrieved 13 August 2024.
This article incorporates text from this source, which is in the public domain.
